CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Operating revenue:
Personalized oncology solutions	$ 1,663	$ 2,264
Translational oncology solutions	7,200	9,286
Total operating revenue	8,863	11,550
Costs and operating expenses:
Cost of personalized oncology solutions	2,733	2,731
Cost of translational oncology solutions	4,900	3,532
Research and development	4,845	2,265
Sales and marketing	4,283	3,155
General and administrative	5,340	6,127
Total costs and operating expenses	22,101	17,810
Loss from operations	(13,238)	(6,260)
Other income/(expense):
Change in fair value of warrant liability	981	(965)
Warrant modification charge	(586)	0
Other expense	(170)	(164)
Total other income/(expense)	225	(1,129)
Net loss before income tax expense	(13,013)	(7,389)
Provision for income tax	127	17
Net loss	$ (13,140)	$ (7,406)
Net loss per common share outstanding basic and diluted (in dollars per share)	$ (0.18)	$ (0.11)
Net loss per common share outstanding diluted (in dollars per share)	$ (0.18)	$ (0.11)
Weighted average common shares outstanding basic and diluted (in shares)	71,824,146	66,863,915